Skip to main content
    C

    Cullinan Oncology LLC (CGEM)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $9.50
    -0.78 (-7.59%)

    Market Cap: $667.39M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Cullinan Oncology LLC (CGEM) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Cullinan Oncology LLC are CytomX Therapeutics (CTMX), Candel Therapeutics (CADL) and Kura Oncology (KURA). By market cap, Cullinan Oncology LLC ranks 6th of the 13 companies on this page; Corvus Pharmaceuticals (CRVS) is the largest at $897.52M. The median P/E of the 3 companies with a P/E is 14.2x.

    Peer Comparison

    CGEM's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Cullinan Oncology LLC (CGEM)$667.39MN/AN/A0.0%N/A0.0%0.00%
    CytomX Therapeutics Inc (CTMX)$444.73MN/A31.0x0.0%-32.8%-71.7%0.00%
    Candel Therapeutics Inc (CADL)$486.37MN/AN/A0.0%-43.5%0.0%0.00%
    Kura Oncology Inc (KURA)$713.90MN/A8.0x0.0%-1125.3%10.1%0.00%
    Immix Biopharma Inc (IMMX)$657.09MN/AN/A0.0%-14.9%0.0%0.00%
    Nuvectis Pharma Inc (NVCT)$696.03MN/AN/A0.0%N/A0.0%0.00%
    Puma Biotechnology Inc (PBYI)$401.70M15.0x1.6x10.3%N/A1.1%0.00%
    Climb Bio Inc (CLYM)$608.53MN/AN/A0.0%N/A0.0%0.00%
    Adlai Nortye Ltd. American Depositary Shares (ANL)$683.26MN/A8.1x-124.8%-7.3%178.1%0.00%
    Corvus Pharmaceuticals Inc (CRVS)$897.52MN/AN/A0.0%N/A0.0%0.00%
    Olema Pharmaceuticals Inc (OLMA)$662.30MN/AN/A0.0%-53.8%0.0%0.00%
    Rigel Pharmaceuticals Inc (RIGL)$837.18M14.2x2.8x106.6%16.7%16.5%0.00%
    CorMedix Inc (CRMD)$370.64M6.3x0.9x15.5%13.9%-47.7%0.00%
    Peer median$659.70M14.2x5.4x0.0%-23.8%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Cullinan Oncology LLC, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    CytomX Therapeutics Inc (CTMX)
    CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company in the United States.
    CTMX competitors
    Candel Therapeutics Inc (CADL)
    Candel Therapeutics Inc. is a pioneering biotechnology company focused on revolutionizing cancer treatment through its proprietary oncolytic virus platform...
    CADL competitors
    Kura Oncology Inc (KURA)
    Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States.
    KURA competitors
    Immix Biopharma Inc (IMMX)
    Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology...
    IMMX competitors
    Nuvectis Pharma Inc (NVCT)
    Nuvectis Pharma, Inc., a biopharmaceutical company, is focused on the development of targeted small molecule therapies for the treatment of cancer.
    NVCT competitors
    Puma Biotechnology Inc (PBYI)
    Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care in the United States...
    PBYI competitors
    Climb Bio Inc (CLYM)
    Climb Bio, Inc., a biotechnology company, focuses on developing therapies for autoimmune-driven inflammatory diseases.
    CLYM competitors
    Adlai Nortye Ltd. American Depositary Shares (ANL)
    Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China.
    Corvus Pharmaceuticals Inc (CRVS)
    Corvus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology therapies.
    CRVS competitors
    Olema Pharmaceuticals Inc (OLMA)
    Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development...
    OLMA competitors
    Rigel Pharmaceuticals Inc (RIGL)
    Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat blood disorders, cancer, and rare immune diseases.
    RIGL competitors
    CorMedix Inc (CRMD)
    CorMedix Inc., a biopharmaceutical company, focuses on developing and marketing therapeutic products for the prevention and treatment of infectious...
    CRMD competitors

    Frequently Asked Questions About CGEM

    Who are Cullinan Oncology LLC's main competitors?

    The companies most similar to Cullinan Oncology LLC include CytomX Therapeutics (CTMX), Candel Therapeutics (CADL), Kura Oncology (KURA), Immix Biopharma (IMMX) and Nuvectis Pharma (NVCT), listed from the closest match.

    Who is Cullinan Oncology LLC's biggest competitor?

    Corvus Pharmaceuticals (CRVS) is the largest of the similar companies at $897.52M; CytomX Therapeutics (CTMX) is the closest match by business profile, size, sector and industry.

    How does CGEM stock compare with its competitors?

    CGEM's net margin is 0.0% against a peer median of 0.0%.

    Which of Cullinan Oncology LLC's competitors pays a higher dividend?

    Cullinan Oncology LLC pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Cullinan Oncology LLC bigger than its competitors?

    No. Cullinan Oncology LLC is 6th by market cap among the 13 companies on this page; the largest is Corvus Pharmaceuticals (CRVS) at $897.52M.